Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 43.48 percent increase over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $4.640 million which beat the analyst consensus estimate of $2.222 thousand by 208.70K percent.